Newsroom

Inquiries

Rory Williams
Director of Communications and Marketing
212-327-8603
[email protected]

Ben Short
Senior Manager of Science Communications and Marketing
212-327-7053
[email protected]

Embargoed media alerts and PIO Tip Sheets

Sign up for a weekly preview of articles to be published in Journal of Cell Biology (JCB), Journal of Experimental Medicine (JEM), Journal of General Physiology (JGP), and Journal of Human Immunity (JHI) by contacting Rory Williams. Media alerts are for journalists only. Rockefeller University Press (RUP) also posts PIO Tip Sheets in EurekAlert every Tuesday to notify authors’ institutions of articles that have been accepted for publication in RUP journals.

Latest Press Releases

First-in-class dual HIF inhibitors eliminate breast, colorectal, melanoma, and prostate tumors in mice when combined with immunotherapy
Researchers at Johns Hopkins University and the University of Maryland School of Pharmacy have developed a set of novel, first-in-class drugs that inhibit hypoxia-inducible factors 1 and 2, a pair of transcription factors considered to be “master regulators” of cancer progression. The study, to be published April 2 in the Journal of Experimental Medicine (JEM), shows that these drugs, when combined with immunotherapy, can completely eliminate breast, colorectal, melanoma, and prostate tumors in mice, suggesting that they could eventually be used to treat a broad range of cancers in humans. Read more...
Apr 2, 2026 10:00 AM

Reactivation of dormant regulatory T cells alleviates asthma symptoms in mice
A collaborative effort between researchers at the Henan Academy of Innovations in Medical Science, Zhengzhou University, and Shenzhen University School of Medicine has provided the first proof-of-principle study demonstrating that targeting a receptor on the surface of anti-inflammatory regulatory T cells (Tregs) can restore their function and alleviate asthma in mice. The study, published March 17 in Life Science Alliance (LSA), shows that targeting the Dectin-1 receptor reprograms the epigenetic landscape of compromised Tregs and renews their ability to express two core Treg genes. These findings offer a promising novel therapeutic avenue for the treatment of allergic asthma and, potentially, other immune-mediated diseases. Read more...
Mar 31, 2026 4:00 PM

Researchers identify new drug target to prevent development of dangerous blood vessel defects in brain
Researchers in the Perelman School of Medicine at the University of Pennsylvania have identified a cell surface receptor protein called TIE2 as the missing link between two key signaling pathways that drive the growth of blood vessel abnormalities known as cerebral cavernous malformations (CCMs). The study, to be published March 27 in the Journal of Experimental Medicine (JEM), suggests that drugs targeting TIE2 could be used to prevent the formation of CCMs, which, if left untreated, can cause brain hemorrhages, strokes, and seizures. Read more...
Mar 27, 2026 10:00 AM

Discovery could improve immune checkpoint inhibitor safety
For many people diagnosed with cancer, treatment with immune checkpoint inhibitors (ICIs) has dramatically extended lives. Some of these treatments, such as Keytruda and Opdivo, have become familiar brand names. However, for some patients, ICI cancer treatment also can prompt the immune system to attack heart tissue—a potentially lethal side effect. Now, scientists at Cincinnati Children’s report discovering a way to dramatically reduce that risk. Details were published Feb 20, 2026, in the Journal of Experimental Medicine. Read more...
Feb 20, 2026

Macrophage immune cells need constant reminders to retain memories of prior infections
Researchers from the University of California, Los Angeles, have discovered that immune cells known as macrophages remain poised to fight repeat infections due to the persistent presence of signaling molecules left behind during previous infections. The study, published February 18 in the Journal of Experimental Medicine (JEM), provides surprising new details about how the body’s innate immune system retains memories of previous immune threats, and suggests new ways to reduce the activity of misprogrammed macrophages that contribute to autoimmune diseases such as lupus and arthritis. Read more...
Feb 18, 2026 10:00 AM

Newly identified protein interaction helps keep cells’ recycling system in balance
Cornell researchers have discovered a new way cells regulate how they respond to stress, identifying an interaction between two proteins that helps keep a critical cellular recycling system in balance. The findings show that a protein called SHKBP1 regulates another protein, p62, which plays a key role in clearing damaged cell components and activating antioxidant defenses. By helping maintain this balance, SHKBP1 allows cells to respond appropriately to stress – a process that can break down in diseases such as cancer and neurodegenerative disorders. Read more...
Feb 9, 2026

Recent media coverage

2/18/2026 — Macrophage immune cells need constant reminders to retain memories of prior infections — Journal of Experimental Medicine
The Scientist, The Microbiologist, GEN News, The Medical News
RUP Press Release - Article

1/20/2026 — Researchers link Alzheimer’s disease protein to development of preeclampsia — Life Science Alliance
Technology Networks, Scimex, MedicalXpress, Healthcare in Europe
RUP Press Release - Article

12/12/2025 — Switching immune cells to “night mode” could limit damage after a heart attack, study suggests — Journal of Experimental Medicine
JAMA Network, GEN News, ABC.es, Focus.it, Hindustan Times, Inkl, The Medical News
RUP Press Release - Article

Embargo policy

Rockefeller University Press (RUP) makes embargoed material available to eligible journalists and public information officers for research articles appearing in its journals: Journal of Cell Biology (JCB), Journal of Experimental Medicine (JEM), Journal of General Physiology (JGP), and Journal of Human Immunity (JHI). Eligible individuals must agree to follow the terms of the RUP embargo policy:

Stories or reports on research articles may not be published or placed in the public domain until 10:00 a.m. US Eastern Time on the day of publication. Precise embargo dates and times are clearly marked on all advance material.
Public information officers (PIOs) may not distribute embargoed materials in the public domain before the embargo date. However, embargoed materials may be distributed to the media by public information officers. Such releases must be clearly identified as embargoed and must include the embargo date and time. PIOs are responsible for taking all necessary steps to ensure that the embargo is honored by all third parties.
All material from RUP journals can be reused without permission for noncommercial purposes, but must be attributed to the appropriate journal and shared expressly under the same restrictions. See our Creative Commons policy for more information.